Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Shares
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
Moderna posts surprise profit, shares spark
(Sharecast News) - Moderna posted a surprise quarterly profit on Thursday, despite sales of its Covid vaccine continuing to slide. The US biotech said revenues in the three months to December-end were $2.8bn, down on the $5.1bn recorded a year earlier but ahead of forecasts for $2.5bn.
Net income tumbled to $217m from $1.5bn, while diluted earnings per share came in at $0.55.
However, while down notably on last year's $3.61, EPS were well above Wall Street forecasts. Most analysts had been expecting a net loss of around $0.97 per share.
As at 1245 GMT, the Nasdaq-listed shares were up 4% in pre-market trading.
The 43% slide in sales of Moderna's Covid vaccine, its only commercial product, was partially offset by a higher average selling price.
Moderna also recorded $600m in deferred revenue from its work with vaccine NGO Gavi during the quarter.
The Covid vaccine, which was granted emergency approval in the US in 2020, was the biotech's first marketable drug.
It generated billions for the firm but demand, in line with all Covid vaccines, has fallen significantly since the peak of the pandemic.
In response, Moderna is looking to adapt the technology for other diseases, most notably for RSV, influenza and cancer.
Stephane Bancel, chief executive, said: "2023 was a year of transition for Moderna as we adapted to the endemic market. At the same time, our development team made significant pipeline advancements across infectious diseases, oncology and rare diseases, while our commercial team increased our Covid-19 market share in the US.
"We look forward to the anticipated approvals of our RSV vaccine beginning in the first half of the year."
Moderna also reiterated its 2024 forecast for sales of $4bn.
Analysts expect the RSV vaccine to generate around $280m in 2024, according to Reuters.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity, Equity & Inclusion | Doing Business with Fidelity | Diversity, Equity & Inclusion Reports | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Staying secure | Statutory and Regulatory disclosures | Whistleblowing programme
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.